EU regulator could issue decision on Pfizer COVID-19 pill 'within weeks'
Reuters
Published Jan 10, 2022 10:18AM ET
(Reuters) - The European Union's drug regulator said on Monday it could issue "within weeks" a decision on whether to approve the use of Pfizer (NYSE:PFE)'s COVID-19 pill, Paxlovid, after the U.S. drugmaker submitted an application seeking authorisation.
The approval sought is for the treatment of mild-to-moderate COVID-19 in patients 12 years of age and older, weighing at least 40 kilograms and are at high risk of their illness worsening, the European Medicines Agency said.
While vaccines are central to the fight against the pandemic, regulators are looking at therapies as a new tool against the fast-spreading Omicron variant, which has now been detected in more than 128 countries around the world.
The EMA has already evaluated a portion of the data during a rolling review of Pfizer's pill that began in November.
Pfizer's two-drug regimen called Paxlovid, which is meant to be taken at home for five days soon after onset of COVID-19 symptoms, was authorized for people aged 12 and older by the U.S. Food & Drug Administration in December.
In a clinical trial, it was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.